<DOC>
	<DOCNO>NCT02552849</DOCNO>
	<brief_summary>This multi-center , non-interventional study ass describe course outcomes patient diagnosed Idiopathic Pulmonary Fibrosis ( IPF ) treat Esbriet ( pirfenidone ) Canada , measure report observe predict forced vital capacity ( FVC ) change baseline ongoing basis .</brief_summary>
	<brief_title>Observational Study Evaluate Disease Course Outcomes Patients Treated With Esbriet ( Pirfenidone ) Idiopathic Pulmonary Fibrosis ( IPF ) Canada</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>&gt; = 18 year age Diagnosis Idiopathic Pulmonary Fibrosis ( IPF ) Prescribed and/or currently take Esbriet ( pirfenidone ) treatment IPF Hypersensitivity Esbriet ( pirfenidone ) Concomitant use fluvoxamine Severe hepatic impairment endstage liver disease Severe renal impairment endstage renal disease require dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>